Title : Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent.

Pub. Date : 2015 May

PMID : 25467961






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The PAR1 inhibitor, vorapaxar (Zontivity, MSD), was recently approved by the FDA for use in the USA for the prevention of thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral artery disease. vorapaxar coagulation factor II thrombin receptor Homo sapiens